Results 1 to 10 of about 10,699 (192)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

Farmacia Hospitalaria, 2019
Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin
Manuel David Gil-Sierra, Leticia García-Mochón, Emilio Jesús Alegre-del Rey, Catalina Alarcón de la Lastra-Romero, Marina Sánchez-Hidalgo   +4 more
doaj   +5 more sources

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence [PDF]

Frontiers in Immunology
Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES.
Elvira Mora, María Laura Fox, María Laura Fox, Angelina Lemes, Beatriz Velasco, Jesús María Hernández-Rivas, Jesús María Hernández-Rivas   +6 more
doaj   +2 more sources

Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan [PDF]

Scientific Reports
Five-year survival in eosinophilic granulomatosis with polyangiitis (EGPA) exceeds 90%, but long-term prognosis is poor. We examined prognosis in 87 Japanese EGPA patients, seen between April 2018 and December 2024, after mepolizumab introduction ...
Yuga Yamashita, Nami Masumoto, Sachiko Takaoka, Takuya Nakashima, Kaho Matsunaga, Yuka Kodama, Kosuke Terada, Hinako Masumitsu, Atsushi Miyasaka, Tatsuya Muraoka, Takeshi Kaneko, Naomi Tsurikisawa   +11 more
doaj   +2 more sources

Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission [PDF]

The Korean Journal of Internal Medicine
Background/Aims This study investigated the clinical efficacy of low-dose mepolizumab (100 mg) in controlling severe eosinophilic asthma, aiming to induce eosinophilic granulomatosis with polyangiitis (EGPA) remission and reduce systemic steroid usage ...
Mi-Ae Kim, Ji-Hyun Lee, Eun-Kyung Kim, Jung-Hyun Kim, Jisoo Park, Se Hee Lee, Tae-Bum Kim   +6 more
doaj   +2 more sources

Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma [PDF]

Journal of Allergy and Clinical Immunology: Global
Background: Real-world evidence on the effectiveness of mepolizumab in children and adolescents with severe asthma (SA) is limited. Objective: We sought to evaluate mepolizumab’s impact on the clinical and health care resource utilization (HCRU) burden ...
Michelle L. Hernandez, MD, Tom Corbridge, MD, François Laliberté, MA, Malena Mahendran, MSc, Annalise Hilts, BA, Kaixin Zhang, MSc, Arijita Deb, PhD   +6 more
doaj   +2 more sources

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab [PDF]

New England Journal of Medicine, 2008
BACKGROUND The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause.
Marc E Rothenberg, Amy D Klion, Peter F Weller   +2 more
exaly   +2 more sources

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Frontiers in Pharmacology, 2023
Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Huqun Li, Chongshu Wang, Aiping Deng, Cuilian Guo   +3 more
doaj   +1 more source

Mepolizumab [PDF]

Hospital Pharmacy, 2016
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Bindler, Ross J, Baker, Danial E   +2 more
openaire   +3 more sources

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review

Respirology Case Reports, 2023
Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life.
Takahiro Matsuyama, Yuya Tomioka, Hiromi Matsuyama, Yusuke Kamenohara, Kengo Tanigawa, Yoichi Dotake, Yoko Hagihara, Koichi Takagi, Kentaro Machida, Hiromasa Inoue   +9 more
doaj   +1 more source

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Allergy, Asthma & Clinical Immunology, 2023
Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics.
Nami Masumoto, Chiyako Oshikata, Ryo Nakadegawa, Yuto Motobayashi, Reeko Osada, Saki Manabe, Takeshi Kaneko, Naomi Tsurikisawa   +7 more
doaj   +1 more source